In yesterday’s Wall Street session, Bioventus Inc (NASDAQ:BVS) shares traded at $5.82, down -2.02% from the previous session.
BVS stock price is now 5.78% away from the 50-day moving average and 27.35% away from the 200-day moving average. The market capitalization of the company currently stands at $371.49M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $7, Canaccord Genuity recently Upgraded its rating from Hold to Buy for Bioventus Inc (NASDAQ: BVS). On August 09, 2023, Craig Hallum Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock increasing its target price from $4 to quote $6, while ‘JP Morgan’ rates the stock as ‘Underweight’
In other news, Singleton Mark Leonard, SVP & CFO sold 4,000 shares of the company’s stock on Apr 11 ’24. The stock was sold for $19,000 at an average price of $4.75. Upon completion of the transaction, the SVP & CFO now directly owns 34,665 shares in the company, valued at $0.2 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 11 ’24, SVP & General Counsel D’Adamio Anthony sold 3,054 shares of the business’s stock. A total of $14,506 was realized by selling the stock at an average price of $4.75. This leaves the insider owning 58,242 shares of the company worth $0.34 million. A total of 43.26% of the company’s stock is owned by insiders.
During the past 12 months, Bioventus Inc has had a low of $2.70 and a high of $7.04. As of last week, the company has a debt-to-equity ratio of 2.36, a current ratio of 1.53, and a quick ratio of 0.97. The fifty day moving average price for BVS is $5.514 and a two-hundred day moving average price translates $4.5813 for the stock.
The latest earnings results from Bioventus Inc (NASDAQ: BVS) was released for 2024-03-30. According to the Medical Devices Company, earnings per share came in at 0.14, beating analysts’ expectations of 0 by 0.14. This compares to -$0.96 EPS in the same period last year. The net profit margin was -4.14% and return on equity was -12.03% for BVS. The company reported revenue of $129.46 million for the quarter, compared to $119.06 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 8.73 percent. For the current quarter, analysts expect BVS to generate $137.59M in revenue.
